Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Damaris Inc. is a forward-thinking biotech company that specializes in the development of personalized medicine solutions. The company's main focus is on creating innovative therapies using genomic data to improve patient outcomes. Damaris Inc. operates at the intersection of healthcare and technology, leveraging advanced bioinformatics tools to identify genetic markers and develop targeted treatments. It plays a significant role in the pharmaceutical industry, impacting areas such as oncology, rare diseases, and chronic conditions. By prioritizing precision medicine, the company aims to revolutionize the way diseases are treated and managed, offering customized treatment plans that cater to individual genetic profiles. Damaris Inc.’s contributions to the medical field are vital, as they align with the broader industry trend towards more personalized and effective healthcare solutions. Through strategic partnerships and research collaborations, Damaris Inc. continues to advance its research pipeline and expand its reach in the burgeoning field of genomic medicine.
Operating margin is thin at 8.43%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 2.5% YoY. The question is whether this is cyclical or a structural shift.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
€2M
▼ -2.5% YoY
Net Income (TTM)
€113K
▲ +29.3% YoY
Op. Margin
8.43%
▲ +2.1pp YoY
ROIC
8.10%
▲ +1.6pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow
N/A
Net Debt
-€92K
Net Cash Position
Cash & Equiv.
€249K
3Y CAGR: -7.1%
Continue Research